来自官方财务报表的收入、利润与现金流历史。
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
| 利润表 | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $0M | $0M | $9M | $2M | $1M | $0M | $0M | $0M | $0M |
| 毛利 | ($206M) | $0M | ($144M) | ($84M) | ($1M) | ($2M) | ($1M) | ($1M) | $0M |
| 毛利率% | — | — | -1682.0% | -3445.8% | -80.0% | — | — | — | — |
| 营业利润（EBIT） | ($357M) | ($326M) | ($200M) | ($126M) | ($215M) | ($167M) | ($62M) | ($36M) | ($23M) |
| 营业利润率% | — | — | -2340.3% | -5164.4% | -14684.8% | — | — | — | — |
| 净利 | ($327M) | ($303M) | ($183M) | ($123M) | ($213M) | ($167M) | ($62M) | ($36M) | ($27M) |
| 净利润率 % | — | — | -2137.5% | -5037.9% | -14554.1% | — | — | — | — |
| EBITDA | ($326M) | ($303M) | ($182M) | ($123M) | ($215M) | ($167M) | ($62M) | ($35M) | ($26M) |
| 每股收益（EPS） | $-13.83 | $-13.48 | $-10.21 | $-18.69 | $-69.33 | $-58.96 | $-24.23 | $-31.01 | $-29.99 |
| 已发行股数 (M) | 29M | 23M | 18M | 7M | 3M | 3M | 3M | 1M | 1M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 PRAX 交互式查看器。 /companies/us/PRAX
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms